Enot, Julyve C.
HRN: 14-88-04 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/30/2022
CO-AMOXICLAV 625MG (TAB)
05/30/2022
06/06/2022
PO
625mg
Q12
UTI; S/P Repair Of 3rd Degree Laceration
Waiting Final Action
Indication: Type of Infection: Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes